Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Wino115on Apr 28, 2023 12:32pm
89 Views
Post# 35419426

RE:RE:RE:RE:RE:RE:RE:RE:Nothing like some 'leaks' on the FDA Resubmission

RE:RE:RE:RE:RE:RE:RE:RE:Nothing like some 'leaks' on the FDA ResubmissionLooks like they made a few pages clearer (Nash bullet points are punchier) and added in the new sort1 data with decent explanations added. Hadn't realized the extent to which that breast cancer data was strong - last dose day 35 but tumor control went another 100 days so something must be going on in those cells.  

Also added the immune cell infiltration as one of the valuable elements to the program. It has it's own box on the summary page now so they must view it as quite important going forward. All just models and still need to get past the lab experiments for anyone to bank on those findings. Like qwerty said, all clinical programs have great pre-clinical. I would add, some pre-clinical can find you partners!  


<< Previous
Bullboard Posts
Next >>